Presentation

Ultimovacs is a Norwegian company that develops immune-stimulatory vaccines to treat a broad range of cancers. The lead universal cancer vaccine UV1 targets human telomerase (hTERT), which drives CD4 T cells to the tumour to activate an immune system cascade. UV1 is currently in a broad Ph2 program in five cancer indications enrolling 650+ patients, in combination with other immunotherapies. Ultimovacs’ second approach is based on the proprietary Tetanus-Epitope-Targeting (TET) platform, which combines tumour-specific peptides and adjuvant in the same molecule.

Recent highlights
In March, Ultimovacs announced that the Ph1 study of UV1 + ipilimumab in malignant melanoma had reached mOS at 66.3 months. In April, Ultimovacs presented TET platform preclinical data showing efficient T cell priming with no suggestion of immunotoxicity, strengthening the ongoing Ph1 TENDU trial. In May, Ultimovacs announced the publication of long-term follow-up data on UV1, showing dynamic T cell responses up to 7.5 years, association of UV1-specific immune responses with longer survival, and synergy between UV1 and checkpoint inhibition. In June, Ultimovacs announced positive 2-year OS data in its ongoing Ph1 study of UV1 + pembrolizumab for malignant melanoma. Across all 30 patients in the study, the 24-month survival rate was 73%, following previously announced 33% complete response rate and
57% objective response rate.

Outlook
In 2022, the company aims to present interim safety data of the Ph1 TENDU trial with the TET platform, update the 3-year OS data of the 1st cohort of the Ph1 study with UV1 + ipilimumab in malignant melanoma, as well as to recruit the first patient in the Ph2 LUNGVAC in NSCLC patients. Top-line results of the Ph2 program in 4 cancer indications are expected in 2023.